Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus alternative administration route of combined MeMuRu-OKA vaccine [MMR varicella zoster virus vaccine] to healthy children aged 11 to 21 months

Next Previous
Trial Profile

Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus alternative administration route of combined MeMuRu-OKA vaccine [MMR varicella zoster virus vaccine] to healthy children aged 11 to 21 months

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MMR-varicella zoster virus vaccine (Primary)
  • Indications Measles; Mumps; Rubella; Varicella zoster virus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 01 Aug 2010 Results published in the European Journal of Pediatrics.
    • 10 Mar 2008 Status changed from in progress to completed. Updated from ClinicalTrials.gov.
    • 02 Nov 2006 Status change
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top